目的 探讨司美格鲁肽联合罗格列酮治疗2型糖尿病的临床疗效。方法 选取2021年5月—2023年7月黄山首康医院内分泌科收治的80例2型糖尿病患者，依据用药情况将所有患者分为对照组和治疗组，每组各40例。对照组患者口服马来酸罗格列酮片，4 mg/次，1次/d。治疗组患者在对照组的治疗基础上皮下注射司美格鲁肽注射液，0.25 mg/次，1次/周；28 d后，0.5 mg/次，1次/周。两组连续用药12周。观察两组的临床疗效和症状好转时间，比较两组治疗前后生活质量评定量表（SF-36）评分、糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2 h PG）、空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）、胰岛β细胞指数（HOMA-β）的变化情况。结果 治疗后，治疗组总有效率是92.51%，显著高于对照组的77.50%（P＜0.05）。治疗后，治疗组多尿、多饮、多食、体质量减少好转时间均显著短于对照组（P＜0.05）。治疗后，两组SF-36评分均较同组治疗前显著提高（P＜0.05）；治疗后，治疗组SF-36评分高于对照组（P＜0.05）。治疗后，治疗组HbA1c、FPG、餐后2 h PG水平均较同组治疗前显著降低（P＜0.05）；治疗后，治疗组糖代谢指标低于对照组（P＜0.05）。治疗后，两组FINS、HOMA-IR水平均显著降低，HOMA-β显著升高（P＜0.05）；治疗后，治疗组FINS、HOMA-IR指标低于对照组，HOMA-β指标高于对照组（P＜0.05）。结论 采用司美格鲁肽和罗格列酮协同治疗2型糖尿病，可较快改善患者临床症状，并有效调节糖代谢相关指标，患者生活质量提升明显，值得借鉴与应用。

Objective To investigate the clinical effect of semaglutide combined with rosiglitazone in treatment of type 2 diabetes. Methods A total of 80 patients with type 2 diabetes admitted to the Department of Endocrinology of Huangshan Shoukang Hospital from May 2021 to July 2023 were selected and divided into control group and treatment group according to drug usage, with 40 patients in each group. Patients in control group were po administered with Rosiglitazone Maleate Tablets, 4 mg/time, once daily. Patients in treatment group were sc administered with Semaglutide Injection on the basis of control group, 0.25 mg/time, once weekly, and after 28 days, 0.5 mg/time, once weekly. Both groups were treated continuously for 12 weeks. The clinical efficacy and symptom improvement time of two groups were observed. The changes of life quality, rating Scale (SF-36), glycated hemoglobin (HbA1c), fasting blood glucose (FPG), 2 h blood glucose (2 h PG), fasting insulin (FINS), insulin resistance value (HOMA-IR) and islet beta cell value (HOMA-β) before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 92.51%, which was significantly higher than that of control group (77.50%, P < 0.05). After treatment, the improvement time of polyuria, polydipsia, polyfood, and body mass reduction in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, SF-36 scores in both groups were significantly higher than those before treatment (P < 0.05). After treatment, the SF-36 score in the treatment group was higher than that in control group (P < 0.05). After treatment, the levels of HbA1c, FPG, and 2 h PG in treatment group were significantly decreased compared with those before treatment (P < 0.05). After treatment, the glucose metabolism index of treatment group was lower than that of control group (P < 0.05). After treatment, FINS and HOMA-IR levels were significantly decreased, but HOMA-β levels were significantly increased in both groups (P < 0.05). After treatment, FINS and HOMA-IR indexes in treatment group were lower than those in control group, but HOMA-β indexes were higher than those in control group (P < 0.05). Conclusion The combination of semaglutide and rosiglitazone in treatment of type 2 diabetes can quickly improve the clinical symptoms of patients, and effectively regulate the related indexes of glucose metabolism, and significantly improve the quality of life of patients, which is worth learning and application.

R977